SEC Form 4 · accession 0001562180-18-002370
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Frates
Director
Period of report
May 8, 2018
Accepted (ET)
May 8, 2018 · 4:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 8, 2018 | M | 7,000 | $8.92 | A | 12,000 | D | |
| Common Stock | May 8, 2018 | S | 7,000 | $154.00 | D | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.92 | May 8, 2018 | M | 7,000 | D | — | May 21, 2024 | Common Stock | 7,000 | 16,809 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2Shares vest 25% on first anniversary of grant and quarterly thereafter beginning on May 26, 2014.